NCT04972539View on ClinicalTrials.gov

Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

March 9, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

AJU-A51 Tab.

Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet

DRUG

A51R1 Tab. and A51R2 Tab.

Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together

Trial Locations (1)

Unknown

Jang Hee Hong, Daejeon

All Listed Sponsors
lead

AJU Pharm Co., Ltd.

INDUSTRY

NCT04972539 - Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults | Biotech Hunter | Biotech Hunter